Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has seen significant short-term growth, outperforming the broader market despite a challenging year. The company has reported strong quarterly results, including high net sales, but faces ongoing financial complexities, including low returns on capital and a negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contributing to a challenging week. Despite a strong monthly performance, year-to-date results remain positive, while one-year performance shows a slight decline. The company has a market capitalization of CNY 23,096 million and positive trends in net sales.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a notable rise in its stock today, reaching an intraday high amid a declining market. Over the past month, the company has significantly outperformed the broader market, although it faces financial challenges, including a low return on capital employed and a negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has seen a notable stock increase, significantly outperforming the China Shanghai Composite. The company has achieved impressive gains over the past week and year-to-date, despite facing challenges such as low return on capital and negative net worth, while reporting positive quarterly results.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has seen a notable increase in stock performance, gaining 7.13% today. Year-to-date, the company has outperformed the China Shanghai Composite, with a 23.42% gain. Despite recent successes, its one-year performance remains negative at -8.31%. The company reported net sales of CNY 217.79 million.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. faced a decline in stock performance, contrasting with the China Shanghai Composite's modest gain. Despite reporting positive net sales for four consecutive quarters, the company shows concerning financial metrics, including a low return on capital employed and a negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a notable stock increase today, contrasting with the decline of the China Shanghai Composite. Despite a challenging year with a significant decline, the company has shown resilience over three years. Financial metrics indicate a strong market cap and recent positive sales results, but challenges remain.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a rise in its stock price today, contrasting with the broader market's performance. Despite recent gains, the company has faced challenges, including a decline over the past week and month, and reports losses alongside a negative net worth, indicating financial difficulties.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline, contrasting with the broader market's performance. Despite reporting positive quarterly results, the company faces financial challenges, including a low return on capital and negative net worth, raising concerns about its long-term growth potential in the pharmaceuticals sector.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with gains in the China Shanghai Composite. The company has struggled over the past year, facing challenges such as a low return on capital employed and a negative net worth, despite reporting positive quarterly results.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a notable intraday gain, contrasting with a decline in the China Shanghai Composite. Despite a challenging year with negative returns, the company has shown resilience year-to-date. Key metrics indicate a large market capitalization and positive quarterly results, though risks remain regarding long-term growth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, reflecting ongoing market challenges. Despite reporting positive quarterly results, the company struggles with low returns and negative net worth. Its one-year performance remains negative, contrasting with the broader market's positive trends. The company's market capitalization is CNY 27,093 million.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a decline in stock price today, contrasting with the overall market's modest gain. Despite recent positive quarterly results and improved operational efficiency, the company has underperformed over the past year, facing challenges such as a negative net worth and low return on capital employed.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has experienced notable stock performance, contrasting with a decline in the broader market. The company has shown consistent quarterly growth in net sales and reduced raw material costs, although it faces challenges such as a low return on capital and negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has recently adjusted its evaluation, reflecting its performance metrics and market position. The company reported net sales of CNY 217.79 million for the quarter ending September 2025, alongside a decrease in raw material costs. However, challenges remain, including a low return on capital employed.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant increase in its stock price today, contrasting with the broader market's performance. Despite recent gains, the company has struggled over the past year, reporting losses and a negative net worth, though it has achieved positive sales results for four consecutive quarters.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a notable intraday gain, contrasting with a decline in the broader market. Despite positive quarterly results, the company has struggled over the past year, facing challenges such as low return on capital and a negative net worth, indicating potential financial risks.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a notable increase on March 16, 2026, contrasting with a slight decline in the China Shanghai Composite. Despite recent gains, the company has faced challenges over the past year, underperforming the broader market, while maintaining a large-cap status in the pharmaceuticals sector.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a decline in stock performance today, contrasting with the minor decrease in the China Shanghai Composite. Despite recent gains over the past week, the company has struggled year-to-date and over the past year, facing challenges such as low returns and negative net worth.